Trial Profile
Phase 1 Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 16 Feb 2024
Price :
$35
*
At a glance
- Drugs Venetoclax (Primary)
- Indications Blastic plasmacytoid dendritic cell neoplasm
- Focus Adverse reactions
- 12 Feb 2024 Planned primary completion date changed from 19 Jan 2024 to 19 Jan 2025.
- 06 Feb 2023 Planned End Date changed from 19 Jan 2023 to 19 Jan 2025.
- 06 Feb 2023 Planned primary completion date changed from 19 Jan 2023 to 19 Jan 2024.